575 related articles for article (PubMed ID: 25101887)
1. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
[TBL] [Abstract][Full Text] [Related]
2. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
[TBL] [Abstract][Full Text] [Related]
3. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
Van Goor F; Hadida S; Grootenhuis PD; Burton B; Cao D; Neuberger T; Turnbull A; Singh A; Joubran J; Hazlewood A; Zhou J; McCartney J; Arumugam V; Decker C; Yang J; Young C; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu P
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18825-30. PubMed ID: 19846789
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
[TBL] [Abstract][Full Text] [Related]
5. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
[TBL] [Abstract][Full Text] [Related]
6. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.
Liu X; Dawson DC
Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434
[TBL] [Abstract][Full Text] [Related]
7. Mutation-specific downregulation of CFTR2 variants by gating potentiators.
Avramescu RG; Kai Y; Xu H; Bidaud-Meynard A; Schnúr A; Frenkiel S; Matouk E; Veit G; Lukacs GL
Hum Mol Genet; 2017 Dec; 26(24):4873-4885. PubMed ID: 29040544
[TBL] [Abstract][Full Text] [Related]
8. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
[TBL] [Abstract][Full Text] [Related]
9. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
Lin WY; Sohma Y; Hwang TC
Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
[TBL] [Abstract][Full Text] [Related]
11. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
[TBL] [Abstract][Full Text] [Related]
12. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
[TBL] [Abstract][Full Text] [Related]
13. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
[TBL] [Abstract][Full Text] [Related]
14. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Yeh JT; Yu YC; Hwang TC
J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
[TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
16. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
[TBL] [Abstract][Full Text] [Related]
17. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based corrector combination restores ΔF508-CFTR folding and function.
Okiyoneda T; Veit G; Dekkers JF; Bagdany M; Soya N; Xu H; Roldan A; Verkman AS; Kurth M; Simon A; Hegedus T; Beekman JM; Lukacs GL
Nat Chem Biol; 2013 Jul; 9(7):444-54. PubMed ID: 23666117
[TBL] [Abstract][Full Text] [Related]
19. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
Yu W; Kim Chiaw P; Bear CE
J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
[TBL] [Abstract][Full Text] [Related]
20. Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.
Veit G; Oliver K; Apaja PM; Perdomo D; Bidaud-Meynard A; Lin ST; Guo J; Icyuz M; Sorscher EJ; Hartman JL; Lukacs GL
PLoS Biol; 2016 May; 14(5):e1002462. PubMed ID: 27168400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
